Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Acquires Open Biosystems to Augment RNAi Portfolio

NEW YORK (GenomeWeb News) - Thermo Fisher Scientific said today that it has acquired Open Biosystems, a privately held provider of RNAi research products, for an undisclosed sum.
Thermo Fisher said in a statement that the acquisition "significantly expands" its presence in the RNAi field because Open Biosystems' specialty, short-hairpin RNA, complements the small-interfering RNA technology it already sells through its Thermo Scientific Dharmacon product line.
"Together, shRNA and siRNA represent the two most widely used RNAi platforms," Thermo Fisher said in a statement.
In addition to RNAi products, Open Biosystems also offers collections of cDNA and open reading frame vectors for gene expression, as well as custom antibody services.
Open Biosystems was founded in 2001 and is based in Huntsville, Ala. Thermo Fisher said that the company had annual revenues of around $14 million in 2007.
Open Biosystems will be integrated into Thermo Fisher's Analytical Technologies Segment.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.